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Huntington Disease (HD) is a genetic neurodegenerative disorder characterized by
broad types of cellular and molecular dysfunctions that may affect both neuronal and
non-neuronal cell populations. Among all the molecular mechanisms underlying the
complex pathogenesis of the disease, alteration of sphingolipids has been identified
as one of the most important determinants in the last years. In the present study,
besides the purpose of further confirming the evidence of perturbed metabolism of
gangliosides GM1, GD1a, and GT1b the most abundant cerebral glycosphingolipids,
in the striatal and cortical tissues of HD transgenic mice, we aimed to test the hypothesis
that abnormal levels of these lipidsmay be found also in the corpus callosumwhitematter,
a ganglioside-enriched brain region described being dysfunctional early in the disease.
Semi-quantitative analysis of GM1, GD1a, and GT1b content indicated that ganglioside
metabolism is a common feature in two different HD animal models (YAC128 and R6/2
mice) and importantly, demonstrated that levels of these gangliosides were significantly
reduced in the corpus callosumwhite matter of bothmodels starting from the early stages
of the disease. Besides corroborating the evidence of aberrant ganglioside metabolism
in HD, here, we found out for the first time, that ganglioside dysfunction is an early event
in HD models and it may potentially represent a critical molecular change influencing the
pathogenesis of the disease.
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INTRODUCTION
Alterations in lipid metabolism have been recently recognized as a novel molecular hallmark that
may profoundly affect brain homeostasis in Huntington’s disease (HD), a rare genetic disorder
characterized by the progressive neurodegeneration and associated motor, cognitive and behavioral
disturbances (The Huntington’s Disease Collaborative Research Group, 1993; Novak and Tabrizi,
2011). The disease-causing mutation is a CAG repeat expansion within the gene encoding
huntingtin (Htt) protein, whose mutated form exerts a variety of undesirable toxic effects in both
neuronal and non-neuronal cells (Bradford et al., 2009, 2010; Hsiao and Chern, 2010). Several
recent studies have indeed largely described oligodendrocytes defects in HD and highlighted a
correlation with cerebral white matter (WM) disorganization either in animal models or in human
patients with the disease (Fennema-Notestine et al., 2004; Ciarmiello et al., 2006; Xiang et al., 2011;
Di Paola et al., 2012, 2014; Huang et al., 2015; Jin et al., 2015; Southwell et al., 2015; Gatto et al.,
2015). The nature of such defects might hypothetically be attributable to an altered lipid/ganglioside
composition of the same brain structures, however much remains to be elucidated.
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Ganglioside GM1, GD1a, and GT1b the most abundant
glycosphingolipids in the Central Nervous System (CNS), are
normally implicated in several physiological events including
regulation of either neuronal or non-neuronal cell function,
maintenance of myelinated fibers and white matter integrity
(Kim, 1990; Posse de Chaves and Sipione, 2010; Schnaar, 2010).
Defective ganglioside content has been widely associated with
white matter abnormalities. Mice lacking some of the enzymes
controlling the synthesis of all three gangliosides showed axonal
degeneration, CNS white matter vacuolization, perturbed myelin
paranodal stability and disruption of axonal-glia interaction
(Sheikh et al., 1999; Yamashita et al., 2005; Sabourdy et al., 2008).
Many previous studies have reported disturbance in
ganglioside metabolism in HD in different brain regions in both
animal models and patients with the disease (Desplats et al.,
2007; Denny et al., 2010; Maglione et al., 2010; Di Pardo et al.,
2014). However, these past studies did not explore the potential
deregulation of this metabolism in the corpus callosum white
matter (CC-WM), where these lipids are recognized to play a
critical role.
White matter abnormalities have been extensively reported
in HD even before overt striatal neuronal loss or occurrence
of clinical signs in both animal models and human patients
(Ciarmiello et al., 2006; Lerch et al., 2008; Di Paola et al., 2012,
2014; Poudel et al., 2014) however, no definitive hypothesis
conceivably explaining the type of dysfunction or its nature has
been advanced so far.
In this study, besides further consolidating the evidence of
aberrant ganglioside metabolism in the striatal and cortical
tissues of HD mice, we extended the analysis also to the cerebral
CC-WM with the aim of finding out any possible link between
FIGURE 1 | Brain ganglioside content is reduced in CC-WM of symptomatic YAC128 HD mice. Representative dot blotting and densitometric analysis of
gangliosides GM1 (A), GD1a (B), and GT1b (C) in CC-WM from symptomatic YAC128 (9 month old) mice and age-matched WT littermates. Ganglioside spots were
visualized by ECL. Data are represented as the mean ± SD, n = 5 for each group of mice. **P < 0.001; ***P < 0.0001 (non-parametric Mann–Whitney U-test).
lipid compositional perturbations and white matter alterations
(Fennema-Notestine et al., 2004; Ciarmiello et al., 2006; Xiang
et al., 2011; Di Paola et al., 2012, 2014; Huang et al., 2015; Jin
et al., 2015; Southwell et al., 2015; Gatto et al., 2015). Interestingly,
in line with our hypothesis our findings demonstrated for the
first time that ganglioside content is abnormal in the CC-
WM of HD models and its deregulation occurs early in the
disease.
MATERIALS AND METHODS
Animal Models
Both R6/2 (carrying approximately 160 ± 5 CAG repeat
expansion) and YAC128 HD mouse colonies were housed in
the animal facility at IRCCS Neuromed. All animal studies were
performed in accordance with approved protocols by the IRCCS
Neuromed Animal Care Review Board and by “Istituto Superiore
di Sanità” (permit number: 1163/2015- PR) and were conducted
according to EU Directive 2010/63/EU for animal experiments.
All the analyses were carried out in pre-symptomatic (4 week
old R6/2; 2.5 month old YAC128), early symptomatic (6 week
old R6/2; 5 month old YAC128) and symptomatic HD mice (12
week old R6/2; 9 month old YAC128) as well as in age-matched
wild-type (WT) littermates.
Total Lysate Preparation
Mice were first sacrificed by cervical dislocation and brains were
removed from the skull. Brains were split in two hemispheres
and ventral sides were placed up, pons was then lifted and
hippocampus removed. Subsequently, CC-WMwas carefully and
gently lifted away from the underlying cortex and collected from
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both hemispheres (Supplementary Figure 1). Cortex and striatum
were finally isolated and placed in separate eppendorf tubes. All
brain regions were snap frozen in liquid N2 and pulverized in a
mortar with a pestle. Tissues were homogenized in lyses buffer
containing 20mM Tris, pH 7.4, 1% Nonidet P-40, 1mM EDTA,
20 mom NaF, 2mM Na3V04, and 1:1000 protease inhibitor
mixture (Sigma-Aldrich) and sonicated with 2 × 10 s pulses.
Tissue lysates were clarified by centrifugation at 10,000 × g
for 15min at 4◦C. Protein concentration was determined by
Bradford method (Bio-Rad Laboratories).
Analysis of Ganglioside Content in Mouse
Brains
To assure that equal amount of homogenate was analyzed,
each sample tissue lysate was serially diluted and protein
concentration was re-assessed by NanoDrop Spectrophotometer.
Fifty picograms of total protein lysates, from both R6/2
and YAC128 HD and control mice were then spotted in
quadruplicates on nitrocellulose membrane and, dot-blotting
analysis was performed as previously reported (Di Pardo et al.,
2014). For GM1 quantitation, membranes were then blocked in
5% milk in TBS-T and incubated with HRP-conjugated cholera
toxin subunit B (5µg/mL) (Invitrogen C34780; lot number:
1306570) for 30min at room temperature. For GD1a and
GT1b gangliosides, membranes were incubated for 3 h at room
temperature with anti-GD1a (1:5000) (Millipore MAB5606; lot
number: 2199592) and anti-GT1b (1:5000) (Millipore MAB5608;
lot number: 2361832), respectively. For GD1a and GT1b a goat
anti-mouse Gig HRP-conjugated secondary antibody (1:5000)
(Santa Cruz sc-2005; lot number: B0813) was used. Ganglioside
spots were detected by ECL Prime (GE Healthcare) and
quantitated with Quantity One (Bio-Rad Laboratories).
Statistics
Non-parametric MannWhitey U was used to analyze ganglioside
content in all experiments. All data were expressed asmean± SD.
RESULTS
Ganglioside Levels Are Perturbed in the
CC-WM from Symptomatic YAC128 Mice
Perturbed ganglioside metabolism in the YAC128 mouse model
was first described by using the Thin Layer Chromatography
(TLC) in the striatal and cortical tissues from symptomatic
mice (Maglione et al., 2010), however, no attention was paid
to ganglioside content in the CC-WM. In order to provide a
more complete scenario about ganglioside profile in HD mice,
here, besides having further confirmed, with a different technical
approach (dot blotting), the alteration of GM1, GD1a, and
GT1b levels in both striatum (Supplementary Figures 2A–C),
and cortex (Supplementary Figures 2D–F) of YAC128 mice,
we examined ganglioside content also in the CC-WM of the
same animals. Interestingly, dot-blotting analysis showed that
all three gangliosides were significantly reduced in this specific
brain region in symptomatic YAC128 mice when compared to
age-matched WT littermates (Figures 1A–C).
Alteration of Ganglioside Metabolism Is
Not Confined to Perturbed GM1 Content in
the Striatum of Symptomatic R6/2 Mice
The finding of GM1 reduction in the striatum of symptomatic
R6/2 mice (Di Pardo et al., 2014 and Supplementary Figure 3)
corroborated the idea of dysfunctional ganglioside metabolism
in HD (Maglione et al., 2010), however did not clarify to what
extend other gangliosides might be also affected in this HD
animal model. Thus, with the aim of addressing this issue,
ganglioside GD1a and GT1b levels were measured in the same
brain tissue of the same mice. Semi-quantitative analysis of
ganglioside content indicated a marked decrease in GD1a levels
in symptomatic (12 week old) R6/2 mice compared to age-
matched control mice (Figure 2A), whereas no changes were
detected in GT1b content (Figure 2B).
Also, we extended the analysis of ganglioside GM1, GD1a, and
GT1b content to different other brain areas of the same mice.
Consistent with reduced levels in the striatal tissues, GM1 was
considerably decreased also in the cortical tissues (Figure 3A).
However, a different profile was observed for GD1a and GT1b,
whose levels were significantly increased in R6/2 compared to
WT control littermates (Figures 3B,C).
Interestingly, when ganglioside analysis was applied to
CC-WM of the same symptomatic R6/2 mice, a dramatic
reduction in the levels of all three gangliosides was detected
(Figures 3D–F).
Early Ganglioside Perturbation in Both
R6/2 and YAC128 Mice
In order to investigate whether the early white matter
abnormalities previously described in HD models (Lerch et al.,
2008; Xiang et al., 2011; Gatto et al., 2015; Jin et al., 2015), may
be associated with any potential alteration of lipid composition,
FIGURE 2 | Levels of ganglioside GD1a are reduced in the striatum of
symptomatic R6/2 mice. Representative dot blotting and densitometric
analysis of GD1a (A) and GT1b (B) in striatal tissues isolated from
symptomatic R6/2 mice and WT controls. Ganglioside spots were visualized
by ECL. Data are represented as the mean ± SD, n = 7 for each group of
mice. ***P < 0.0001 (non-parametric Mann–Whitney U-test).
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FIGURE 3 | Levels of brain gangliosides are aberrant also in the cortex and CC-WM from symptomatic R6/2 HD mice. Representative dot blotting and
densitometric analysis of gangliosides GM1, GD1a, and GT1b in cortex (A–C) and CC-WM (D–F) from symptomatic (12 week old) R6/2 mice and age-matched WT
littermates. Ganglioside spots were visualized by ECL. Data are represented as the mean ± SD, n = 7 for each group of mice. *P < 0.05; **P < 0.001; ***P < 0.0001
(non-parametric Mann–Whitney U-test).
levels of gangliosides GM1, GD1a, and GT1b in the CC-WM
of both pre-symptomatic and early symptomatic R6/2 and
YAC128 mice were determined. Interestingly, warning signs of
dysfunctional ganglioside metabolism were detected at the pre-
symptomatic stage before any visible disease symptoms in R6/2
mice. While the concentration of both GM1 and GT1b did
not change between pre-symptomatic R6/2 mice (4 week old)
and age-matched controls (Figures 4A–C), GD1a content was
significantly reduced in R6/2 animals when compared to WT
littermates (Figure 4B). A different scenario emerged in the CC-
WM from pre-symptomatic YAC128 mice, where no changes
were found in none of the gangliosides analyzed (Figures 4D–F).
Coherent with our expectation, analysis of ganglioside content
in tissues from early symptomatic (6 week old) R6/2 mice
confirmed the reduction of GD1a content observed at the
pre-symptomatic stage (Figure 5B) and revealed that such a
reduction spread also to GT1b (Figure 5C). Likewise, YAC128
mice also exhibited significant reduction of both GD1a and GT1b
at similar disease stage (5 month old mice) (Figures 5E,F). No
variations in GM1 content were observed either in R6/2 or in
YAC128 mice (Figures 5A,D) not even at this disease stage.
DISCUSSION
In this study, we confirmed our previous finding of altered
glycolsphyngolipid metabolism in HD and importantly
highlighted, for the first time, the evidence that such a defect
is not confined to the striatal and cortical tissues, but rather
extended also to other brain regions like CC-WM, that has been
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FIGURE 4 | Levels of ganglioside GD1a are reduced in CC-WM levels from pre-symptomatic R6/2 HD mice. Representative dot blotting and densitometric
analysis of gangliosides GM1, GD1a, and GT1b in CC-WM from pre-symptomatic R6/2 (4 week old) (A–C) and YAC128 (2.5 month old) (D–F) and age-matched WT
littermates. Ganglioside spots were visualized by ECL. Data are represented as the mean ± SD, n = 5 for each group of mice. **P < 0.001 (non-parametric
Mann–Whitney U-test).
reported being strongly implicated in the pathophysiology of HD
(Rosas et al., 2010; Bohanna et al., 2011; Di Paola et al., 2012).
Interestingly, the generalized reduction of GM1 in all brain
tissues from both symptomatic HD mice was associated with
perturbed regulation of other two specific gangliosides GD1a
and GT1b, whose content was differentially distributed among
striatum, cortex and CC-WM. These findings found support on
previous studies reporting a brain region-changing profile for
both GD1a and GT1b in both HD animals and human patients
(Desplats et al., 2007; Denny et al., 2010; Maglione et al., 2010).
Unlike what happens in other brain regions, CC-WM showed a
concomitant and significant reduction of all three gangliosides
in the symptomatic stage of the disease in both animal models.
Interestingly, first signs of aberrant ganglioside metabolism in
CC-WM were represented by a selective reduction of GD1a
and GT1b content and were first detected in early-symptomatic
stage of the disease. Moreover, GD1a content was significantly
perturbed even before any disease symptoms appeared in R6/2
mice and no variation was detected in pre-symptomatic YAC128
mice. Although not clear yet, one of the possible factors that
may lead to such a differential disease stage-dependent decrease
of ganglioside levels, may be related to the effect on mutant Htt
on the regulation of gene expression and/or activity of enzymes
involved in the synthesis and degradation of each ganglioside,
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FIGURE 5 | Levels of gangliosides GD1a and GT1b are reduced in CC-WM from early symptomatic R6/2 and YAC128 HD mice. Representative dot
blotting and densitometric analysis of gangliosides GM1, GD1a, and GT1b in CC-WM from early symptomatic R6/2 (6 week old) (A–C) and YAC128 (5 month old)
(D–F) and age-matched WT littermates. Ganglioside spots were visualized by ECL. Data are represented as the mean ± SD, n = 5 for each group of mice. **P <
0.001; ***P < 0.0001 (non-parametric Mann–Whitney U-test).
already reported in both HD animal models and human patients
(Desplats et al., 2007; Maglione et al., 2010; Denny et al., 2010).
This hypothesis could likely explain also the slight difference
between R6/2 and YAC128 mice in the timing when signs of
ganglioside deficiency first appear.
Although we cannot establish a definitive correlation between
ganglioside composition and the CC-WM abnormalities
reported in HD (Lerch et al., 2008; Rosas et al., 2010; Bohanna
et al., 2011; Di Paola et al., 2012; Di Pardo et al., 2014), we
certainly speculate that the early reduction of GD1a and GT1b
may conceivable contribute to callosal axon disorganization
and, more in general, to the early axonal dysfunction and
degeneration that may precede neuronal loss in HD pre-clinical
models (Li et al., 2001; Lerch et al., 2008; Gatto et al., 2015)
and eventually support the evidence of “dying-back” pattern of
neurodegeneration in HD (Han et al., 2010). In the light of that,
we hypothesize that the axonal dysfunction potentially resulting
from ganglioside deficiency may represent the molecular event
underlying the impairment of brain connectivity occurring
in HD patients and in HD mutation-carriers (Rosas et al.,
2010; Di Paola et al., 2012; Dumas et al., 2013; Poudel et al.,
2014).
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Collectively, our data confirmed the aberrant ganglioside
metabolism in HD, supported the idea that gangliosides are
relevant determinants in the pathogenesis of the disease and
importantly, for the first time, highlighted an early, and gradual
perturbation of ganglioside content in the CC-WM in two HD
transgenic mouse models. However, further studies are now
needed to definitely clarify any functional role of ganglioside
perturbation in the onset and progression of white matter
abnormalities in HD and to understand how specific CC-WM
drug targets can be approached in the future.
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